When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?

J Clin Med. 2023 Jul 10;12(14):4581. doi: 10.3390/jcm12144581.

Abstract

Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].

Publication types

  • Editorial

Grants and funding

This research received no external funding.